Response evaluation of locoregional therapies in combined hepatocellular–cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study

2021 ◽  
Author(s):  
A. Mukund ◽  
S. V. Srinivasan ◽  
S. Rana ◽  
R. Vijayaraghavan ◽  
Y. Patidar ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Intrahepatic Cholangiocarcinoma ◽  
Response Evaluation ◽  
Combined Hepatocellular Cholangiocarcinoma ◽  
Locoregional Therapies ◽  
Matched Study

Laparoscopic versus open liver resection for hepatocellular carcinoma: Case-matched study with propensity score matching

2015 ◽  
Vol 63 (3) ◽  
pp. 643-650 ◽  
Author(s):  
Ho-Seong Han ◽  
Ahmed Shehta ◽  
Soyeon Ahn ◽  
Yoo-Seok Yoon ◽  
Jai Young Cho ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Resection ◽  
Propensity Score ◽  
Propensity Score Matching ◽  
Open Liver Resection ◽  
Matched Study

Segmental Yttrium-90 Radioembolization versus Segmental Chemoembolization for Localized Hepatocellular Carcinoma: Results of a Single-Center, Retrospective, Propensity Score–Matched Study

2017 ◽  
Vol 28 (6) ◽  
pp. 777-785.e1 ◽  
Author(s):  
Siddharth A. Padia ◽  
Guy E. Johnson ◽  
Kathryn J. Horton ◽  
Christopher R. Ingraham ◽  
Matthew J. Kogut ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Single Center ◽  
Matched Study ◽  
Yttrium 90

scholarly journals Outcomes of resection for hepatocellular carcinoma with macroscopic bile duct tumour thrombus: A propensity score matched study

2020 ◽  
Vol 20 (4) ◽  
pp. 1-1
Author(s):  
Qiyu Chi ◽  
Zheng Shi ◽  
Zhibo Zhang ◽  
Xiang Zhang ◽  
Li Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Bile Duct ◽  
Propensity Score ◽  
Tumour Thrombus ◽  
Matched Study

Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study

2021 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Ching-Sheng Hsu ◽  
Tzu-Rong Peng ◽  
Ta-Wei Wu ◽  
Chao-Chuan Wu ◽  
Sou-Yi Chang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Real World ◽  
Transarterial Chemoembolization ◽  
Matched Study

scholarly journals Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis

Liver Cancer ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 744-755
Author(s):  
Francesco Tovoli ◽  
Pietro Guerra ◽  
Massimo Iavarone ◽  
Letizia Veronese ◽  
Matteo Renzulli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Liver Cirrhosis ◽  
Propensity Score ◽  
Intrahepatic Cholangiocarcinoma ◽  
Lead Time ◽  
Propensity Score Analysis ◽  
Lead Time Bias ◽  
Cirrhotic Patients ◽  
Surgical Treatments

<b><i>Background:</i></b> Due to its poor survival, intrahepatic cholangiocarcinoma (ICC) is held to be a much more aggressive cancer than hepatocellular carcinoma (HCC). In most published series, patients were diagnosed when symptomatic. However, ICC is now increasingly being discovered during the surveillance for HCC in cirrhosis. Whether this earlier detection of ICC is associated with an equally dismal prognosis or not is unknown. <b><i>Methods:</i></b> This is amulticenter retrospective study of consecutive ICC patients. Patients were stratified into subgroups according to the absence/presence of cirrhosis. A propensity score matching was performed to reduce the potential biases. Cirrhotic patients were further stratified according to their surveillance status. The lead-time bias and its potential effects were also estimated. <b><i>Results:</i></b> We gathered 184 patients. Eighty-five patients (46.2%) were cirrhotic. Liver cirrhosis was not related to a worse overall survival (33.0 vs. 32.0 months, <i>p</i> = 0.800) even after the propensity score analysis (43.0 in vs. 44.0 months in 54 pairs of patients, <i>p</i> = 0.878). Among the cirrhotic population, 47 (55.3%) patients had received a diagnosis of ICC during a surveillance programme. The 2 subgroups differed in maximum tumour dimensions (30 vs. 48 mm in surveyed and non-surveyed patients, respectively). Surveyed patients were more likely to receive surgical treatments (59.8 vs. 28.9%, <i>p</i> = 0.003). Overall survival was higher in surveyed patients (51.0 vs. 21.0 months, <i>p</i> &#x3c; 0.001). These benefits were confirmed after correcting for the lead-time bias. <b><i>Conclusions:</i></b> Cirrhotic patients have different clinical presentation and outcomes of ICC according to their surveillance status. In our series, ICC in cirrhosis was not associated with worse OS. Cirrhosis itself should not discourage either surgical or non-surgical treatments.

Sign in / Sign up

Export Citation Format

Share Document